Performance of the VERSANT ® HIV-1 Resistance Assays (LiPA) for detecting drug resistance in therapy-naive patients infected with different HIV-1 subtypes

In this study we evaluated the performance of the VERSANT ® HIV-1 Resistance Assays (LiPA) in detecting drug resistance in therapy-naive HIV-infected patients diagnosed in Belgium in 2000. We compared the results with population sequencing and found concordance to be in line with previous studies in...

Full description

Saved in:
Bibliographic Details
Published inFEMS immunology and medical microbiology Vol. 39; no. 2; pp. 119 - 124
Main Authors Derdelinckx, Inge, Van Laethem, Kristel, Maes, Bart, Schrooten, Yoeri, De Schouwer, Kirsten, De Wit, Stéphane, Fransen, Katrien, Garcı́a Ribas, Sergio, Moutschen, Michel, Vaira, Dolores, Zissis, Georges, Van Ranst, Marc, Van Wijngaerden, Eric, Vandamme, Anne-Mieke
Format Journal Article Web Resource
LanguageEnglish
Published Oxford, UK Elsevier B.V 28.11.2003
Blackwell Publishing Ltd
Elsevier Science Bv
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:In this study we evaluated the performance of the VERSANT ® HIV-1 Resistance Assays (LiPA) in detecting drug resistance in therapy-naive HIV-infected patients diagnosed in Belgium in 2000. We compared the results with population sequencing and found concordance to be in line with previous studies in treatment-experienced patients (86.87% for reverse transcriptase (RT); 92.77% for protease (PRO)). Discordance was mainly due to indeterminate reactions on LiPA (8.45% for RT; 6.85% for PRO) and minor discordances (4.13% for RT; 0.25% for PRO). Major discordances were rare (0.46% for RT; 0.12% for PRO). Indeterminate reactions were significantly associated with strains belonging to non-B subtypes.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
scopus-id:2-s2.0-0242558933
ISSN:0928-8244
1574-695X
DOI:10.1016/S0928-8244(03)00240-2